SCHEMBL16629892

SCHEMBL16629892

Cc1nnc2ccc(CN(C)C(=O)OC(C)(C)C)cn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.39
SLC6A4 P31645 5/20 0.39
GLS O94925 3/20 0.39
CACNA1G O43497 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNA1C Q13936 1/20 0.34
AAK1 Q2M2I8 1/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
APLNR P35414 1/20 0.33
BRD4 O60885 2/20 0.32
HTR2A P28223 1/20 0.32
CTSL P07711 1/20 0.32
CTSB P07858 1/20 0.32
CTSS P25774 1/20 0.32
RIPK1 Q13546 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
NCOR2 Q9Y618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29990519 0.75 HTR2C (0.39) HTR2CSLC6A4GLSCACNA1GCACNA1B
SCHEMBL25546128 0.74 HSP90AA1 (0.43) HTR2CSLC6A4GLSCTSLCTSB
SCHEMBL23448763 0.72 HRH3 (0.44) HTR2CSLC6A4GLSCTSLCTSB
SCHEMBL21278579 0.72 HTR2C (0.40) HTR2CSLC6A4GLSCACNA1GCACNA1B
SCHEMBL1935308 0.71 PPARG (0.46) HTR2CSLC6A4GLSCACNA1GCACNA1B
SCHEMBL2229917 0.71 MTOR (0.48) HTR2CSLC6A4GLSCTSLCTSB
SCHEMBL7430459 0.70 RIPK1 (0.59) HTR2CSLC6A4HTR2ARIPK1
SCHEMBL1935742 0.70 AKT1 (0.43) HTR2CSLC6A4GLSCACNA1GCACNA1B
SCHEMBL30264860 0.70 ALDH1A1 (0.57) HTR2CSLC6A4RIPK1
SCHEMBL8139521 0.70 TPSAB1 (0.47) HTR2CSLC6A4GLSCACNA1GCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HTR2C 333/4885SLC6A4 1966/4885GLS 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.